Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat

Impact · against what's priced in

The article provides no new material for JNJ, as the earnings beat, guidance raise, and MedTech headwinds were already reflected in the current valuation. The stock's short-term volatility does not change the underlying requirement for revenue acceleration to justify a higher multiple.

JNJ+0.00

Already priced in

The price assumes

The raised 2026 revenue guidance of $100.3–$101.3 billion and adjusted EPS of $11.45–$11.65

The article confirms that JNJ beat estimates and modestly raised full-year guidance, both of which the market already assumed in its current pricing.

What JNJ's price assumes · Sep 3

• JNJ▲1569%
• china▲9%
• earnings▲8%
• guidance
• healthcare
• geopolitics
• etf